News

New study looks at use of Riluzole to slow Alzheimer's progression

Published Date:

Riluzole is an FDA-approved drug, currently used to treat amyotrophic lateral sclerosis (ALS; Lou Gehrig's disease) and is currently in a Phase II clinical trial for the treatment of mild Alzheimer’s disease (AD) (Clinical Trial #NCT01703117). The exact reason behind riluzole’s potential benefits on cognition in AD patients is unknown. One potential way may be through altering glutamate signaling in the brain, a neurotransmitter essential for learning and memory.

A team of researchers at the Center for Alzheimer’s Disease and Related Disorders at SIU Medicine lead by Kevin N. Hascup, PhD, and Erin R. Hascup, PhD, recently published a study in the Journal of Neurochemistry with the intent to determine the long-term therapeutic benefits of early riluzole treatment in the AβPP/PS1 mouse model of Alzheimer’s disease. The researchers determined that early intervention with riluzole was able to restore a specific type of communication between cells in the brain, glutamatergic neurotransmission, and delay or prevent learning and memory deficits associated with Alzheimer’s disease.

Overall, the results of this study lend further support of the use of riluzole as an early therapeutic intervention strategy to delay or prevent cognitive decline and restore the way cells communicate in the brain.

More from SIU News

2025 Pharmacology Awards Event

2025 Pharmacology Awards honor determination & scientific excellence

The Department of Pharmacology at SIU School of Medicine held its 2025 Awards, celebrating the dedication and scientific achievements of its students and researchers. The annual event highlighted
Wei Du and the THUNDER Imager

SIU labs can bring the THUNDER with new 3D imaging microscope

A new microscope at SIU School of Medicine can quickly make the invisible visible. The THUNDER Imager TM , a highly advanced technology now in use at SIU’s Core Research Facilities, lets scientists
test tubes

A Torry Testimonial

SIU scientist Andy Wilber know Dr. Don Torry well, and believes he personifies the '3 Ts of research' at the medical school.